Abstract
Metaplastic carcinoma is an uncommon variant of breast cancer. It carries a worse prognosis than the usual epithelial neoplasms of the breast. It is clinically and radiologically indistinguishable from the common variants of breast cancer, and it is a pathologic diagnosis. The optimum management approach is unknown and it has been usually managed like matched stage invasive ductal carcinoma. Research is ongoing to explore the potential benefit of tyrosine kinase inhibitors in the systemic management of metaplastic breast carcinoma.